Showcases the Safety Profile of High Dose Nicotinamide Riboside in Parkinson's Disease in the Phase 1 NR-SAFE Trial.

Published Date: 24 Dec 2023

In a recent study, researchers did not find any reports of moderate or severe adverse events in Parkinson disease patients receiving a high dose of nicotinamide riboside therapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot